ConductScience.org, home
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
API referenceFor AI assistants

Trial · NCT01425008

Participant flow114

How many started, completed or left each group, period by period.

61 to 80 of 114

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Dose Expansion PhaseSTARTEDQ2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)0
Dose Expansion PhaseSTARTEDQ2D Dose Escalation Phase: TAK-580 200 mg (22 Days Cycle)0
Dose Expansion PhaseSTARTEDQ2D Dose Escalation Phase: TAK-580 280 mg (22 Days Cycle)0
Dose Expansion PhaseSTARTEDQ2D Dose Escalation Phase: TAK-580 200 mg (28 Days Cycle)0
Dose Expansion PhaseSTARTEDQW Dose Escalation Phase: TAK-580 400 mg (28 Days Cycle)0
Dose Expansion PhaseSTARTEDQW Dose Escalation Phase: TAK-580 600 mg (28 Days Cycle)0
Dose Expansion PhaseSTARTEDQW Dose Escalation Phase: TAK-580 800 mg (28 Days Cycle)0
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: TAK-580 (BRAF+ Naive)16
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: TAK-580 (BRAF+ Previously Treated)8
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: TAK-580 (NRAS+ Naive)16
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: TAK-580 (NRAS+ Previously Treated)1
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: TAK-580 BRAF/NRAS WT+ Naive6
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase:TAK-580 BRAF/NRASWT+PreviouslyTreated11
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: Pharmacokinetic Cohort20
Dose Expansion PhaseSTARTEDQ2D Dose Expansion Phase: TAK-580 (BRAF+)2
Dose Expansion PhaseSTARTEDQW Dose Expansion Phase: TAK-580 NRAS WT+ Naive19
Dose Expansion PhaseCOMPLETEDQ2D Dose Escalation Phase: TAK-580 20 mg (22 Days Cycle)0
Dose Expansion PhaseCOMPLETEDQ2D Dose Escalation Phase: TAK-580 40 mg (22 Days Cycle)0
Dose Expansion PhaseCOMPLETEDQ2D Dose Escalation Phase: TAK-580 80 mg (22 Days Cycle)0
Dose Expansion PhaseCOMPLETEDQ2D Dose Escalation Phase: TAK-580 135 mg (22 Days Cycle)0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01425008/flow?page=4

API referenceFor AI assistants